Intercept Pharmaceuticals financials at a glance
| Year | Year | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$2.45M | $1.62M | $1.74M | $2.78M | $24.95M | $130.96M | $179.80M | $252.00M | $312.69M | $363.47M | $285.71M | $0.00M | $0.00M |
| GM % | Gross Margin % |
|
100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 98.95% | 98.60% | 98.33% | 98.30% | 99.15% | 99.66% | 0.00% | 0.00% |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -252.31% | -158.78% | -123.98% | -69.27% | -15.34% | -23.88% | 0.00% | 0.00% |
| EPS | Earnings Per Share |
|
$-2.46 | $0.00 | |||||||||||
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.00% | 0 |
| Sha. | Shares |
|
16.51m | 19.34m | 21.36m | 24.33m | 24.81m | 25.1m | 29.65m | 32.73m | 32.99m | 29.55m | 29.71m | 0m | 0m |
| OCF | Operating Cash Flow |
|
$-15.75M | $-28.01M | $-87.74M | $-162.90M | $-342.44M | $-265.40M | $-240.71M | $-236.61M | $-170.03M | $-41.64M | $-26.78M | $0.00M | $0.00M |
| FCF | Free Cash Flow |
|
$-15.79M | $-29.64M | $-92.38M | $-168.84M | $-347.52M | $-275.79M | $-240.88M | $-237.75M | $-173.92M | $-42.04M | $-27.35M | $0.00M | $0.00M |
| FCFS | Free Cash Flow Per Share |
|
$-2.51 | $-1.64 | $-4.44 | $-7.13 | $-14.09 | $-11.01 | $-8.46 | $-7.51 | $-5.28 | $-1.32 | $-0.81 | $0.00 | $0.00 |